Biotech

Biotech’s coming of age: AI, capital efficiency and China reshape the field

Biotech’s coming of age is being framed by three documented shifts: investor caution, AI-driven efficiency, and China’s growing role in drug development. This plan keeps the article tightly grounded in Nature Biotechnology and PubMed-confirmed facts.

America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings

BIO's whitepaper argues that small and mid-sized biotechs are central to U.S. innovation, advancing early-stage science into therapies with the help of investor capital, partnerships, and CDMOs. It highlights their outsized role in employment, clinical trials, FDA filings, and new drug development.

Biotech coming of age: market analysis of a sector in transition

Biotech is back, according to Nature Biotechnology, but the sector’s contours are changing as investor caution, China’s rise and fast-moving AI reshape the market. This plan stays tightly grounded in the cited article and avoids unsupported forecasts or quantitative claims.

SLS Stock Jumps on Biotech Momentum as SELLAS Gains 25.10%

SELLAS Life Sciences Group Inc. shares advanced 25.10% amid reported biotech momentum. The cited sources confirm the company’s clinical-stage oncology profile and SEC listing details.

Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)

Puma Biotechnology granted inducement awards to new employees under Nasdaq Listing Rule 5635(c)(4) on June 3, 2026. The move signals strategic talent acquisition and potential pipeline focus.

4 Biotech Stocks Investors Should Watch in 2026: Market Analysis

This article highlights four biotech stocks—Argenx, BeOne Medicines, IQVIA, and BioNTech—with implied upside ranging from 28% to 41% in 2026. It provides catalyst-driven analysis for investors and pharma BD teams.

AI Titans Push Congress for DNA Safeguards: Implications for Biotech Strategy

OpenAI, Anthropic, Inceptive Nucleics, and Grail are urging Congress to enact DNA safeguards, signaling a shift in the regulatory landscape for genomic data. This article analyzes the competitive and strategic implications for biotech firms.

Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner

Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.